

State of Oklahoma SoonerCare Rozlytrek[®] (Entrectinib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
Drug Information		
harmacy billing (NDC:) Start Date (or date of next dose):		
	Regimen:	
Billing Provider Information		
Provider NPI:	Provider Name:	
Provider Phone:	Provider Fax:	
Prescriber Information		
Prescriber NPI: Prescriber Name:		
Prescriber Phone:	_ Prescriber Fax:	Specialty:
Criteria Cri		
For Initial Authorization:		
1. Please indicate the diagnosis and information:		
□ Non-Small Cell Lung Cancer (NSCLC)		
A. Is disease metastatic? Yes No		
B. Is tumor ROS1-positive? Yes No		
C. Will entrectinib be used as a single agent? Yes No		
□ Solid Tumors		
A. Does diagnosis include NTRK gene fusion without a known acquired resistance mutation?		
Yes No		
B. Is disease metastatic? Yes No		
C. Is member a surgical candidate? Yes No		
D. Has disease progressed following treatment? Yes No		
E. Is a satisfactory alternative therapy available? Yes No		
F. Will entrectinib be used as single agent? Yes No		
☐ If answer is none of the above, please indicate diagnosis:		
Additional Information:		
For Continued Authorization:		
1. Date of last dose:		
Does patient have any evidence of progressive disease while on entrectinib therapy? Yes No		
3. Has the member experienced any adverse drug reactions related to entrectinib therapy? Yes No No		
· · · · · · · · · · · · · · · · · · ·		
If yes, please specify adverse reactions: Additional Information:		
		_ Date:
	notes. Specific information will	information is true and correct to the best of my be requested if necessary. Failure to complete this

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 134 5/23/2023